This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Aug 2011

Marshall Reports NV-128 Pre-Clinical Study Results

The oncology company plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug application to the US FDA by the first quarter of 2012.

San Diego-based oncology company Marshall Edwards has announced the pre-clinical study results of NV-128 in chemotherapy-resistant ovarian cancer stem cells.


The study demonstrated that NV-128 can specifically target the mitochondria in patient-derived ovarian cancer stem cells to induce cell death in chemo-resistant cell population.


Previous studies showed that NV-128 is able to inhibit tumour growth in an ovarian cancer animal model without inducing significant toxicity.


It found that once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be more potent than NV-128 in pre-clinical research studies.

Related News